• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers
Home / Science / Technology / shRNA

shRNA

shRNA Platform

Short hairpin RNA (shRNA) technology offers differentiated strategy to future development of CAR T

Celyad Oncology’s shRNA technology allows for the modulation of gene expression in our CAR T constructs without the need for gene-editing. We are currently engineering T-cells with specific desired features, including the inhibition of alloreactivity, increased persistence and enhanced antitumor activity or potentially improved tolerability. We have also validated the utility of our shRNA platform with our next-generation NKG2D receptor CAR T clinical candidate, CYAD-02, which incorporates a single shRNA hairpin targeting the NKG2D ligands MICA/MICB within the construct.

 

981_9238-1

Our shRNA platform provides a versatile approach to the design and development of next-generation CAR T candidates with the potential to work with a broad array of CAR T constructs

Innovative technology built for allogeneic CAR T

Our CYAD-200 series of allogeneic CAR T candidates use shRNA to interfere with the expression of the TCR by knockdown of the RNA encoding the CD3ζ component of the TCR complex. Data from preclinical studies have shown shRNA knockdown targeting CD3ζ is as effective as gene-editing methods such as CRISPR/Cas9. In addition, preclinical data demonstrated expression of a single shRNA hairpin provides prolonged TCR knockdown.

The technology is also complementary to our All-in-One Vector approach, which allows for the expression of multiple shRNA hairpins in a single construct within a single transduction step. Data from preclinical studies demonstrate simultaneous knockdown of the multiple gene products at the mRNA and protein levels in a single multiplexed vector.

Celyad Oncology’s lead shRNA-based allogeneic CAR-T candidate, CYAD-211, which uses a single shRNA to knockdown the CD3ζ component of the TCR complex, is expected to enter the clinic by year-end 2020.

Learn about Our Manufacturing

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy